It was 20 years ago that de Klein et al. (1982) heralded the first chapter of the story of the molecular basis of the Ph-chromosome. We reported that the human ABL gene was translocated from chromosome 9 to chromosome 22 to generate the Ph-chromosome. Of course, the story of the Ph-chromosome did not start in 1982. In 1960, Nowell and Hungerford identified an abnormal G group chromosome with a deletion on the q arm in chronic myelogenous leukemia. Rowley (1973) , using improved banding techniques, showed that there was a translocation from chromosome 22q11 to another chromosome, usually chromosome 9. It is now known that the part of chromosome 9 that translocates to chromosome 22 and contains the most important part of the Ph-chromosome was too small to be visualized by the cytogenetic techniques used at the time. Figure 1 illustrates the chromosomes involved in the Philadelphia translocation.
Our involvement in leukemia research started when we joined John Stephenson's Laboratory of Viral Carcinogenesis at the NCI in Frederick, MD in 1981. At the time, the finding that cellular homologs of retrovirally transduced oncogenes existed was novel, and we molecularly cloned the human homologs of v-fes and v-fms Heisterkamp et al., 1983a) . Moreover, by using a v-abl probe, we detected many hybridizing bands in total human DNA on a Southern blot, indicating that there were sequences in the human genome that contained significant homology to v-abl, and that c-ABL could be a relatively large gene. Thus, we set about to clone human c-ABL. Molecular cloning was a relatively new technology then. One of us (John) returned to England, where he had worked as a student, to construct a human cosmid library in the laboratory of Richard Flavell at the MRC in London. Cosmid cloning was new and had the distinct advantage that it allowed one to double the size of clonable inserts. We isolated the main body of the ABL exons in the form of three cosmids, which spanned 64 kb and spent many hours constructing a simple restriction enzyme map (Heisterkamp et al., 1983b) .
Sequencing was then a time-consuming matter, using either a chemical or a chain-termination method. Sequence analysis established the presence of a phosphotyrosine acceptor site in v-ABL and human c-ABL, revealing that they were very conserved and moreover closely resembled those of v-src, v-yes and vfes/fps .
Few genes had, at that point in time, been mapped to specific human chromosomes. The use of somatic cells hybrids, which retained a limited number of human chromosomes, to determine such localization of genes was another novel development. In collaboration with Walter Bodmer's group in the UK, c-ABL was localized to human chromosome 9 . Members of the Department of Cell Biology and Genetics at the Erasmus University in Rotterdam including Gerard Grosveld and Annelies de Klein were focused on investigating the molecular biology of the Ph-positive leukemia, and they had generated somatic cell hybrids that retained the Phchromosome or the 9q+ chromosome. At the time, it was not known whether the Ph-chromosome contained material originating from chromosome 9, although it was clear that a segment from chromosome 22 did move to chromosome 9. Thus, although it was a far shot, we decided to investigate if ABL was involved in this translocation. The resulting collaboration between the Laboratory of Viral Carcinogenesis and the Department of Cell Biology showed, to our surprise and delight, that c-ABL was not present on the 9q+ chromosome, but instead was located on the Ph-chromosome (de Klein et al., 1982) . Moreover, c-ABL was found to translocate to the Phchromosome even in patients with complex chromosomal translocations but not in two Ph-negative CML patients with apparently normal karyotypes (Bartram et al., 1983) .
What did this mean? Even though the segment of chromosome 9 containing c-ABL was too small to be seen using standard techniques available at the time, that still did not say much about c-ABL having a possible direct role in the causation of this type of leukemia. The orientation of c-ABL on chromosome 9 wasn't known either. We had cloned the main body of the c-ABL exons using v-ABL probes, but did the gene have additional upstream exons? Unfortunately, clones containing more 5' sequences were absent from our cosmid library. Because of this, overlapping phage clones were isolated, containing sequences more 5' of c-ABL and these, in turn, were used to clone additional segments of DNA. Much later, the true size of the entire ABL gene was determined and its most 5' exon was found located around 200 kb away from exon 2.
Splenectomy was frequently used to treat CML patients then. We had obtained frozen spleen tissue from a number of CML patients through the NIH Resources and Logistics branch and isolated DNA from them. Using probes from the newly cloned segments of ABL, we scanned many DNAs for abnormalities using Southern blots. The ultimate reward for this research efforts came with the discovery that one patient DNA showed a germline and an abnormal band with a probe of the newly cloned 5' ABL region, and the germline and a different abnormal band with a second probe upstream from the first. The fragments we saw were chimeric DNAs from the 22q7 and 9q+ chromosomes. We cloned the 9q+ fragment from a phage library constructed from that patient's DNA and showed that the 3' end of that fragment was chromosome-22-derived, using somatic cell hybrids. This also showed that the translocation between chromosomes 22 and 9 was, in fact, reciprocal (Heisterkamp et al., 1983c) .
We had jumped to the region on chromosome 22 in which one Ph-positive CML patient had a breakpoint. This provided a probe for that region, and enabled us to molecularly clone a chromosome 22 DNA segment from normal DNA. Seventeen of 19 DNAs from CML patients were found to have a breakpoint within a limited region of around 5.8 kb, for which we proposed the term 'breakpoint cluster region' (bcr) (Groffen et al., 1984) . Was this area part of a gene? To investigate this, we isolated fragments of DNA from that region which were used to 'fish' for cDNAs. A partial cDNA, containing the C-terminal end of a gene was isolated. Using this cDNA fragment, the placement of exons with respect to the translocation breakpoints could be determined (Figure 2 , M BCR, and Heisterkamp et al., 1985) . This analysis showed that the chromosomal breakpoints were located within introns of a gene. Since the gene shared no homology to other genes that had been isolated till then, it was named the BCR gene Shtivelman et al., 1985) .
Abnormal ABL mRNAs of 8.5 kb had been detected in CML patient samples Collins et al., 1984; Gale and Canaani, 1984) using ABL probes. We analysed the RNAs of five CML patients with probes from both ABL and BCR and demonstrated that there was an abnormal mRNA of around 8.5 kb present in these patient samples that hybridized to both ABL and 5' BCR probes and thus represented a chimeric BCR/ABL mRNA . Shtivelman et al. (1985) also showed that CML cells contained fused transcripts of BCR/ABL and Mes- defined the complete coding region using overlapping cDNA clones. Finally, antisera were used to show that the fusion transcripts are translated into a Bcr/Abl fusion protein (BenNeriah et al., 1986; Stam et al., 1987) . We also established that the normal Bcr gene encodes a 160 000-Da phosphoprotein with associated serine/ threonine kinase activity (Stam et al., 1987) . These data together with the seminal findings that Bcr/Abl has a tyrosine kinase activity (Kloetzer et al., 1985; Konopka et al., 1985) and its requirement for transformation (Pendergast et al., 1993) further provided all the evidence to implicate the direct product of the Ph-translocation in leukemia.
The most common chimeric BCR/ABL mRNA found in CML patients contains a relatively large BCR part and encodes a P210 Bcr/Abl fusion protein (Figure 2 ). Soon it was realized that there were also Ph-positive acute lymphoblastic leukemia patients that did have a BCR/ABL translocation but lacked a chromosomal breakpoint within the most common region, the major breakpoint cluster region or M BCR (Erikson et al., 1986) . However, an abnormallysized c-ABL mRNA was present (de Klein et al., 1986) . We then showed that such breakpoints occurred more 5' of the breakpoint cluster region in the m BCR (Figure 2) (Hermans et al., 1987) , within what turned out to be the first intron of the BCR gene . These chimeric mRNAs produced a P190 Bcr/Abl fusion protein (Chan et al., 1987) . Direct demonstration that BCR/ ABL causes leukemia was established in transgenic experiments by Suzannne Cory's group (Hariharan et al., 1989 ) using a bcr/v-Abl construct and our work using a replica construct of P190 BCR/ABL (Heisterkamp et al., 1990). 
Looking back
In this manner, the Ph-chromosome became, together with the t(8;14) in Burkitt's lymphoma, the first consistent chromosome abnormality associated with human cancer, to which the translocation of a protooncogene had been documented (Dalla-Favera et al., 1982; Taub et al., 1982) . With the advent of the completed sequence of the human genome, we now have a very refined appreciation how large one single band on a chromosome can be in terms of kilobase pairs. Fortunately, at the time we decided to start cloning human c-ABL, we were not aware of this. It was also a stroke of luck that of the various CML DNAs we looked at, one had a breakpoint relatively close to the main body of ABL exons (Heisterkamp et al., 1983c) . Nowadays, when one looks back upon those experiments, one marvels at the amount of effort that went into generating these data and the amount of time that would have to be spent on it now. Probably, those three years of work would currently be compressed to less than 3 months, since cloning of large pieces of DNA is routine and sequencing is automated. In fact, both ABL and BCR genes were largely sequenced in 1995 before completion of the human genome project (Chissoe et al., 1995) . The story of Bcr/Abl illustrates the fact that the pace of discovery is sometimes determined by available technical advances as well as luck.
One could argue that for 20 years of work, a host of controversies have cropped up, but few definitive answers to basic questions regarding the mechanisms of how Bcr/Abl causes leukemia. However, on the positive side, patients with Ph-positive leukemias now have a drug available that targets the deregulated Abl protein and shows great therapeutic promise (reviewed by Mauro et al., 2002; Goldman, 2001 ). In addition, other drugs are in the pipeline (Reichert et al., 2001; Peters et al., 2001) . In short, although we undoubtedly have learned a lot in the past 20 years, we are in no danger of running out of questions to ask and investigate in the area of BCR/ABL-caused leukemia.
Lessons from Crkl: discrepancies between the results obtained with mouse models and other experimental approaches Current research efforts emphasize the mechanisms by which Bcr/Abl causes leukemia. The best molecular 13 and 14) . Above the exons, the approximate location of the different protein domains as encoded by the different exons is also shown. This includes exon 1, encoding the serine/threonine kinase, the DH-PH domains that share homology to proteins with guanidine nucleotide exchange factor activity towards members of the Rho family of GTPases, the C2-homology domain of which the function within Bcr is not known, and the GTPase activating protein (GAP) domain, that encodes GAP activity for the small GTPase Rac. The Bcr/Abl fusion proteins (bottom panel) contain a constant Abl moiety encompassing exons 2 -11 and a variable Bcr part as indicated. P190 fusion proteins are generated as the fusion of exons e1a2, whereas the two common P210 variants are known as b2a2 and b3a2. A rare variant encoding a P230 is generated by an e19a2 fusion candidates would ideally be brought forward by different experimental systems, including in vitro work, tissue culture models, mouse models, and human patient material. During the last 10 years, more candidates have been identified than we had bargained for. One that has been examined extensively in our laboratory is a protein that we have named Crkl (Crklike) because of its homology to Crk. We will discuss it briefly below because it illustrates the difficulties in unraveling the mechanisms of leukemogenesis.
In 1992, Freed and Hunter reported the detection of a very prominently tyrosine phosphorylated protein of around 41 kDa in Ph-positive CML patient material (Freed and Hunter, 1992) . While cloning genes upstream of BCR on chromosome 22, we fortuitously cloned CRKL and demonstrated that it encodes the prominently phosphorylated 41 kDa protein. Crkl consists of an SH2 domain and two SH3 domains, the most N-terminal one of which binds to a polyproline-rich region in the Abl part of BCR/ABL. Crkl becomes transiently tyrosine phosphorylated during many signaling events such as those involving cytokine receptors or integrins. It is however constitutively tyrosine phosphorylated in cells that express Bcr/Abl and forms a stable complex with the oncoprotein (recently reviewed by Feller, 2001 ). Based on the consistency with which Crkl is found tyrosine phosphorylated by and complexed to Bcr/Abl and its involvement in integrin/cytokine signaling, it was an interesting candidate for a key role in transduction of the oncogenic signals of Bcr/Abl. Moreover, ablation of Crkl protein levels using antisense technology, or blocking the interaction of Crkl with Bcr/Abl through the use of peptides that block binding of the Crkl SH3 domain, is growth-inhibitory for CML blast cells (Tari et al., 1997; Kardinal et al., 2000) .
These results suggest that ablation of Crkl in vivo would retard leukemogenesis. To test this, we generated crkl null mutants. In a mixed genetic background, these mice are viable and fertile. Then, through breeding, we obtained matched cohorts of crkl null, P190 and crkl wt, P190 mice. Analysis of the rate of death due to leukemia/lymphoma showed that there was no statistically significant difference. We could find no evidence that the related Crk protein was quantitatively compensating for lack of Crkl in the null mutant lymphomas (Hemmeryckx et al., 2002) . Does this mean that Crkl is not important in the generation of leukemia by Bcr/Abl? We would argue that the answer to this is: No. Just the fact, that complete loss of Crkl function allows normal murine embryonic development in certain genetic backgrounds, whereas it is embryonic lethal in others, tells us that there are other proteins that functionally compensate for lack of Crkl. These pathways possibly also compensated for the lack of Crkl in P190-generated leukemia. Indeed, by the examination and comparison of the signaling in leukemia/lymphomas caused by P190 in the presence or absence of Crkl, we may be able to identify those proteins that are used by Bcr/Abl in the absence of Crkl.
But why, then, do antisense Crkl oligonucleotides and blocker peptides have an effect on the growth of Bcr/Abl-expressing cells? Tari et al. (1997) used three different cell lines established from Ph-positive patients, and the effect of Crkl antisense may relate to the inherently different adaptive properties of cells grown for numerous generations in culture. Kardinal et al. (2000) treated peripheral blood-derived blast cells from 16 different CML patients with blocker peptides for 3 days. Of these, 11 showed inhibition of proliferation, with 36 -73% of the cells remaining alive as judged by trypan blue exclusion. Thus, not all cells within a sample died, nor did all samples respond with growth inhibition. This could indicate that there are subpopulations of cells that do not lean heavily upon Crk(l) function for survival and others that do. It would be of great interest to be able to follow such cells over a prolonged period of time of treatment, to see if they would be able to evade this inhibition imposed by blocking of Crk(l) function.
Looking forward
We ourselves and others have identified various signaling proteins phosphorylated by Bcr/Abl. However, the identification of the key signaling proteins in the process of Bcr/Abl-caused leukemogenesis was found to be much more difficult than anticipated.
Although there is a massive amount of information on this topic, the single protein or pathway through which Bcr/Abl would cause leukemia, if it actually exists, has to date not been identified, with the exception of the Bcr/Abl tyrosine kinase itself. Within the next decade, microarray profiling, proteomics and mass spectrometry will probably provide us with a complete inventory of all the proteins that are affected by Bcr/Abl. However, such list will not necessarily tell us what is important or even what is required. Each individual candidate will have to be tested in a biological system and, chances are, that no single protein will be found to be essential. In fact, Koh and Daley (2001) argued, that Bcr/Abl does not activate a single signaling pathway, but rather the multifaceted communication network of the cytokine system, as well as other tumorigenic signals. In that context, they have called Bcr/Abl 'the ultimate oncoprotein'. If the mechanism by which Bcr/Abl causes leukemia actually consists of an attack on the cell's normal anti-cancer defenses from different angles (eventually finding a 'weak spot' that results in the development of overt leukemia), other oncogenes will surely operate using similar strategies! Basic research into the pathobiology and signal transduction of Bcr/Abl will undoubtedly provide us with a wealth of information regarding many normal and abnormal biological systems. If BCR/ABL is indeed 'the ultimate oncogene', much will be learned that will be useful for the understanding of the development of other types of human cancer as well. It follows, that this will ultimately result in the development of new rational therapeutics for other malignancies, as well as for those Ph-positive patients that have leukemia refractory to STI571 (Gleevec) treatment.
